Skip to main content
. Author manuscript; available in PMC: 2014 Jun 27.
Published in final edited form as: J Thorac Cardiovasc Surg. 2013 Nov 4;147(5):1668–1677.e5. doi: 10.1016/j.jtcvs.2013.09.041

Figure 1.

Figure 1

Intratracheal injection of PMSCs and PMSCCM attenuated the development of BO on day 28 after tracheal transplantation. A, Representative images of H&E staining of the allograft 28 days after transplantation. The magnification of all images is 4×. +PMSCs, Treated with PMSCs (1 × 106); +PBS, treated with 1× PBS as the control; +PMSCCM, treated with PMSCCM; +CONM, treated with blank medium as the control. B, Bar graph of luminal obliteration of the allografts with PMSC (n = 13) and PMSCCM (n = 8) on day 28. Data shown are the mean ± standard error of mean. PMSC, Placenta-derived human mesenchymal stem cells; PBS, phosphate-buffered saline; PMSCCM, PMSC-conditioned medium; CONM, control media.